前列腺癌患者血液中PSA、TAP、MACC1的表达及其诊断价值

doi:10.3969/j.issn.1674-8115.2022.04.012

上海交通大学学报（医学版） ›› 2022, Vol. 42 ›› Issue (4): 496-501.doi: 10.3969/j.issn.1674-8115.2022.04.012

前列腺癌患者血液中PSA、TAP、MACC1的表达及其诊断价值

王慧¹(), 赵莹¹, 温丽蓉², 曹军³, 羊继平⁴, 原永明¹()

^1.上海市徐汇区大华医院检验科，上海 200237
^2.上海交通大学医学院附属瑞金医院检验科，上海 200025
^3.上海市徐汇区大华医院介入肿瘤科，上海 200237
^4.上海市徐汇区大华医院泌尿外科，上海 200237

收稿日期:2021-12-13 接受日期:2022-03-09 出版日期:2022-04-28 发布日期:2022-04-28
通讯作者: 原永明 E-mail:13761013468@163.com;13916312382@139.com
作者简介:王慧（1982—），男，主管技师，学士；电子信箱：13761013468@163.com。
基金资助:
上海市徐汇区智慧医疗研究项目(XHZH202102)

Diagnostic value of PSA, TAP and MACC1 expression in blood of patients with prostate cancer

WANG Hui¹(), ZHAO Ying¹, WEN Lirong², CAO Jun³, YANG Jiping⁴, YUAN Yongming¹()

^1.Department of Laboratory, Dahua Hospital, Xuhui District, Shanghai 200237, China
^2.Department of Labratory, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
^3.Department of Interventional Oncology, Dahua Hospital, Xuhui District, Shanghai 200237, China
^4.Department of Urology, Dahua Hospital, Xuhui District, Shanghai 200237, China

Received:2021-12-13 Accepted:2022-03-09 Online:2022-04-28 Published:2022-04-28
Contact: YUAN Yongming E-mail:13761013468@163.com;13916312382@139.com
Supported by:
Xuhui Smart Medical Research Project(XHZH202102)

摘要/Abstract

摘要：

目的·探讨前列腺癌患者血液中前列腺特异抗原（prostate specific antigen，PSA）、肿瘤异常蛋白（tumor abnormal protein，TAP）及结肠癌转移相关基因1（colon cancer metastasis related gene 1，MACC1）的表达及临床诊断价值。方法·以2019年1月至2020年12月于上海市徐汇区大华医院就诊的107例前列腺癌患者为病例组，另选择同期该院60名健康体检者为对照组。回顾性分析2组患者血液中PSA、TAP及MACC1的水平，及其与Gleason评分、T分期的相关性；采用受试者操作特征（receiver operating characteristic，ROC）曲线评价各项指标诊断前列腺癌的灵敏度和特异度。结果·病例组患者血液PSA、TAP及MACC1水平均显著高于对照组（P<0.05）；随着 Gleason 分级的升高，病例组患者血液PSA、TAP及MACC1水平逐渐升高；随着T分期的进展，病例组患者血液PSA、TAP及MACC1水平逐渐升高；有淋巴结转移的患者血液PSA和MACC1水平高于无淋巴结转移患者，TAP水平低于无淋巴结转移患者，差异均有统计学意义（P<0.05）。血液PSA诊断前列腺癌的ROC曲线下面积（area under the curve，AUC）为0.764，灵敏度为86.12%，特异度为88.63%，截断值为6.01 μg/L；血液TAP诊断前列腺癌的AUC为0.796，灵敏度为88.18%，特异度为89.58%，截断值为135.62 μm²；血液MACC1诊断前列腺癌的AUC为0.873，灵敏度为78.46%，特异度为80.10%，截断值为37.80 pg/mL；3项指标联合检测的AUC 为0.941，灵敏度为93.15%，特异度为94.08%，均高于各单项指标（P<0.05）。Spearman相关分析结果显示，血液PSA、TAP及MACC1水平均与Gleason评分呈正相关（r值分别为0.648、0.513和0.501，均P=0.000），与T分期呈正相关（r值分别为0.616、0.537和0.542，均P=0.000）。结论·前列腺癌患者血液PSA、TAP及MACC1水平均与Gleason评分、T分期之间关系密切，对前列腺癌有一定的诊断价值；3项联合检测，诊断价值更高。

关键词: 前列腺特异抗原, 肿瘤异常蛋白, 结肠癌转移相关基因1, 前列腺癌, Gleason评分, T分期

Abstract:

Objective·To investigate the expression and diagnostic value of prostate specific antigen (PSA), tumor abnormal protein (TAP) and colon cancer metastasis related gene 1 (MACC1) in the blood of patients with prostate cancer.

Methods·One hundred and seven patients with prostate cancer (case group) admitted to Dahua Hospital, Xuhui District, Shanghai, from January 2019 to December 2020 were retrospectively analyzed, and 60 healthy people (control group) who underwent physical examination in the hospital in the same period were selected. The levels of blood PSA, TAP and MACC1 in the two groups, as well as their correlation with Gleason score and T stage, were analyzed. Receiver operating characteristic (ROC) curve was used to evaluate the value of various indexes in the diagnosis of prostate cancer.

Results·The levels of blood PSA, TAP and MACC1 in the case group were significantly higher than those in the control group (P<0.05). With the increase of Gleason grade, the levels of blood PSA, TAP and MACC1 increased gradually. With the progress of T stage, the levels of blood PSA, TAP and MACC1 increased gradually. The levels of PSA and MACC1 in the patients with lymph node metastasis were significantly higher than those without lymph node metastasis, but the levels of TAP in the patients with lymph node metastasis were significantly lower than those without lymph node metastasis (P<0.05). The analysis results of ROC curve showed that the AUC of PSA in the diagnosis of prostate cancer was 0.764, the sensitivity was 86.12%, the specificity was 88.63%, and the cut-off value was 6.01 μg/L. The AUC of TAP in the diagnosis of prostate cancer was 0.796, the sensitivity was 88.18%, the specificity was 89.58%, and the cut-off value was 135.62 μm². The AUC of MACC1 in the diagnosis of prostate cancer was 0.873, the sensitivity was 78.46%, the specificity was 80.10%, and the cut-off value was 37.80 pg/mL. The AUC (0.941), sensitivity (93.15%) and specificity (94.08%) of combined detection were higher than those of any single detection (P<0.05). Spearman correlation analysis showed that the blood PSA, TAP and MACC1 levels were positively correlated with Gleason score (r=0.648, 0.513, 0.501; P=0.000), and with T stage (r=0.616, 0.537, 0.542; P=0.000).

Conclusion·Blood PSA, TAP and MACC1 are closely related to Gleason score and T stage of prostate cancer, which has some value in the diagnosis of prostate cancer, and the combined detection of three items has higher diagnostic value.

Key words: prostate specific antigen (PSA), tumor abnormal protein (TAP), colon cancer metastasis related gene 1 (MACC1), prostate cancer, Gleason score, T stage

中图分类号:

R737.25

王慧, 赵莹, 温丽蓉, 曹军, 羊继平, 原永明. 前列腺癌患者血液中PSA、TAP、MACC1的表达及其诊断价值[J]. 上海交通大学学报（医学版）, 2022, 42(4): 496-501.

WANG Hui, ZHAO Ying, WEN Lirong, CAO Jun, YANG Jiping, YUAN Yongming. Diagnostic value of PSA, TAP and MACC1 expression in blood of patients with prostate cancer[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2022, 42(4): 496-501.

图/表 3

参考文献 17

1	刘畅, 王庆伟, 罗振宇, 等.SKP2、kindlin-2在前列腺癌组织中的表达及其与患者临床特征的关系[J].癌症进展, 2019, 17(6):727-730.
	LIU C, WANG Q W, LUO Z Y, et al.Expression of SKP2 and kindlin-2 in prostate cancer and the relationship with clinical characteristics[J].Oncol Prog, 2019, 17(6):727-730.
2	陈勇杰, 许春. miR-18a在前列腺癌患者血清中的表达及其临床意义[J]. 国际泌尿系统杂志, 2020(1): 34-37.
	CHEN Y J, XU C.Expression of miR-18a in serum of patients with prostate cancer and its clinical significance[J].Int J Urol Nephrol,2020(1): 34-37.
3	Chung H Y, Kim J H, Han I H, et al. Polarization of M2 macrophages by interaction between prostate cancer cells treated with trichomonas vaginalis and adipocytes[J]. Korean J Parasitol, 2020, 58(3): 217-227.
4	王长春, 尹水平, 李家山, 等. 前列腺特异性抗原联合肿瘤异常蛋白对前列腺癌的诊断价值[J]. 临床泌尿外科杂志, 2019, 34(10): 791-795.
	WANG C C,YIN S P, LI J S, et al. Clinical value of PSA combined with TAP in the diagnosis of prostate cancer[J].J Clin Urol, 2019, 34(10): 791-795.
5	郑建坤, 周园, 宏小翠, 等. 结肠癌转移相关基因1和胸苷激酶1在前列腺癌组织的表达及其临床意义[J]. 中华实验外科杂志, 2018, 35(12): 2196-2198.
	ZHEN J K, ZHOU Y, HONG X C, et al.Study of the expression of metastasis-associated in colon cancer 1, thymidine kinase 1 and the clinical significance of prostate carcinoma[J].Chin J Exper Surg,2018, 35(12): 2196-2198.
6	中国医师协会放射肿瘤治疗医师分会, 中华医学会放射肿瘤治疗学分会, 中国抗癌协会肿瘤放射治疗专业委员会. 中国前列腺癌放射治疗指南(2020年版)[J]. 中华肿瘤防治杂志, 2021, 28(5): 323-337.
	Radiation Tumor Therapy Branch of Chinese Medical Association, Chinese Society of Radiation Oncology, Tumor Radiation Therapy Professional Committee of Chinese Anti-Cancer Association.Guidelines for radiotherapy of prostate cancer in China (2020 Edition)[J].Chin J Cancer Prev Treat, 2021, 28(5): 323-337.
7	中华医学会病理学分会泌尿与男性生殖系统疾病病理学组. 前列腺癌规范化标本取材及病理诊断共识(2021版)[J]. 中华病理学杂志, 2021, 50(9): 994-1001.
	Pathology Group of Urological and Male Reproductive System Diseases, Pathology Branch of Chinese Medical Association. Consensus on standardized specimen selection and pathological diagnosis of prostate cancer (2021 edition)[J].Chin J Pathol, 2021, 50(9): 994-1001.
8	吴怀申, 何雍毅. 恶性肿瘤的TNM分类法[J]. 癌症, 1999,18(1): 104-105.
	WU H S, HE Y Y.TNM classification of malignant tumors[J].Cancer,1999, 18(1): 104-105.
9	International Agency for Research on Cancer. Latest global cancer data: cancer burden rises to 19.3 million new cases and 10.0 million cancer deaths in 2020[EB/OL].(2020-12-15)[2021-12-15].https://www.iarc.who.int/news-events/latest-global-cancer-data-cancer-burden-rises-to-19-3-million-new-cases-and-10-0-million-cancer-deaths-in-2020.
10	姚韧寰, 王红梅, 胡敏, 等. 前列腺癌ADC值与血清IL-6、VEGF、PSA的相关性分析[J]. 现代肿瘤医学, 2019, 27(10): 1757-1760.
	YAO R H, WANG H M, HU M, et al. Analysis of correlation between ADC value and serum IL-6,VEGF,PSA in prostate cancer[J].Modern Oncol, 2019, 27(10): 1757-1760.
11	李绍成, 骆本军, 罗建蓉. 前列腺癌患者血清PSA表达情况及PCNA表达的相关性研究[J]. 中国性科学, 2018, 27(8): 14-18.
	LI S C, LUO B J, LUO J R. The expression of serum PSA in patients with prostate cancer and its correlation with the expression of PCNA[J]. Chin J Hum Sex, 2018, 27(8): 14-18.
12	蒋丽琳, 肖南平, 蒋欢. 胃癌组织中BRCA1蛋白表达、血清TAP水平变化与铂类化疗效果的关系分析[J]. 癌症进展, 2019, 17(6): 715-718.
	JIANG L L, XIAO N P, JIANG H. Relationship between expression of BRCA1 protein,serum TAP and the efficacy of platinum-based chemotherapy in patients with gastric cancer[J].Oncol Prog, 2019, 17(6): 715-718.
13	Welch H G, Albertsen P C. Reconsidering prostate cancer mortality: the future of PSA screening[J]. N Engl J Med,2020,382(16):1557-1563.
14	杨双祥, 周永安, 黄娅芬, 等. 腹腔镜宫颈癌根治术后TAP、CEA水平变化及其临床意义[J]. 局解手术学杂志, 2018, 27(6): 447-450.
	YANG S S, ZHOU Y A, HUANG Y F, et al.Changes in TAP and CEA after laparoscopic radical resection of cervical cancer and their clinical significance[J].J Reg Anat Oper Surg, 2018, 27(6): 447-450.
15	刘伟刚, 刘家炜, 王旭东. 前列腺癌患者血清MACC1的表达水平及其与临床病理参数和预后的关系[J]. 解放军预防医学杂志, 2019, 37(8): 65-66.
	LIU W G, LIU J W, WANG X D.Serum MACC1 expression level and its relationship with clinicopathological parameters and prognosis in patients with prostate cancer[J].J Prev Med Chin Peopl Liber Army,2019, 37(8): 65-66.
16	韩刚, 龚航军, 曹羽, 等. 结肠癌患者血清MACC1、CEA表达水平与腹腔镜术后复发转移的相关性[J]. 中国现代普通外科进展, 2019, 22(10): 757-760.
	HAN G, GONG H J, CAO Y, et al. Correlation of serum MACC1 and CEA levels with recurrence and metastasis after laparoscopic surgery in patients with colon cancer[J].Chin J Curr Adv Gen Surg, 2019, 22(10): 757-760.
17	陈钇地, 龙莉玲, 彭鹏, 等. DCE-MRI定量参数与前列腺癌Gleason评分及血清PSA相关性分析的价值[J]. 临床放射学杂志, 2018, 37(10): 1693-1697.
	CHEN Y D, LONG L L, PENG P, et al. The value of correlation analysis between quantitative parameters of DCE-MRI with gleason score of prostate cancer and serum PSA[J].J Clin Radiol, 2018, 37(10): 1693-1697.

Group	PSA/ （μg‧L^-1）	TAP/μm²	MACC1/ （ng‧mL^-1）
Case group （n=107）	14.35±5.13	174.58±19.63	52.41±12.89
Control group （n=60）	4.16±1.34	74.29±8.04	29.84±6.33
t value	15.082	37.796	12.718
P value	0.000	0.000	0.000

Group	PSA/ （μg‧L^-1）	TAP/μm²	MACC1/ （ng‧mL^-1）
Case group （n=107）	14.35±5.13	174.58±19.63	52.41±12.89
Control group （n=60）	4.16±1.34	74.29±8.04	29.84±6.33
t value	15.082	37.796	12.718
P value	0.000	0.000	0.000

Clinic pathologic feature	n	PSA/ （μg‧L^-1）	TAP/μm²	MACC1/ （ng‧mL^-1）
Age
<65 years	54	14.15±5.08	175.54±20.15	52.18±12.91
≥65years	53	14.55±5.26	173.60±20.25	52.64±13.07
t/F value		0.400	0.467	0.183
P value		0.689	0.620	0.855
Gleason score
2‒4 score	7	9.25±4.12	148.34±18.58	39.95±10.23
5‒7 score	48	14.08±5.03	172.18±19.22	50.89±12.83
8‒10 score	52	19.31±5.19	201.41±19.34	65.66±13.04
t/F value		20.599	42.023	23.543
P value		0.000	0.000	0.000
T satge
T1	29	9.14±3.26	146.12±19.12	40.16±10.25
T2	47	14.19±4.89	168.58±19.58	51.97±12.78
T3‒T4	31	17.79±4.93	199.37±20.12	60.58±12.83
t/F value		27.629	56.084	21.247
P value		0.000	0.000	0.000
Lymphatic metastasis
Yes	62	16.58±6.12	121.48±20.59	73.53±6.58
No	45	11.28±5.89	147.07±19.87	37.08±5.03
t/F value		4.492	6.439	31.127
P value		0.000	0.000	0.000

Clinic pathologic feature	n	PSA/ （μg‧L^-1）	TAP/μm²	MACC1/ （ng‧mL^-1）
Age
<65 years	54	14.15±5.08	175.54±20.15	52.18±12.91
≥65years	53	14.55±5.26	173.60±20.25	52.64±13.07
t/F value		0.400	0.467	0.183
P value		0.689	0.620	0.855
Gleason score
2‒4 score	7	9.25±4.12	148.34±18.58	39.95±10.23
5‒7 score	48	14.08±5.03	172.18±19.22	50.89±12.83
8‒10 score	52	19.31±5.19	201.41±19.34	65.66±13.04
t/F value		20.599	42.023	23.543
P value		0.000	0.000	0.000
T satge
T1	29	9.14±3.26	146.12±19.12	40.16±10.25
T2	47	14.19±4.89	168.58±19.58	51.97±12.78
T3‒T4	31	17.79±4.93	199.37±20.12	60.58±12.83
t/F value		27.629	56.084	21.247
P value		0.000	0.000	0.000
Lymphatic metastasis
Yes	62	16.58±6.12	121.48±20.59	73.53±6.58
No	45	11.28±5.89	147.07±19.87	37.08±5.03
t/F value		4.492	6.439	31.127
P value		0.000	0.000	0.000

[1]	宋绪佳1，张时君2，吕文鑫1，黄林1，张言1，吴明贵1，谢少伟2. 基于单壁碳纳米管的化学 - 光热协同治疗去势抵抗性前列腺癌的研究[J]. 上海交通大学学报（医学版）, 2020, 40(4): 450-.
[2]	洪西 1，刘利杰 1，黄先玉 2，罗静 2，俞建军 1. 溴结构域蛋白 4抑制剂对前列腺癌细胞组蛋白巴豆酰化修饰以及增殖、迁移的影响[J]. 上海交通大学学报（医学版）, 2019, 39(7): 721-.
[3]	谢少伟 1，董柏君 2，夏建国 1，王艳青 2，李红丽 1，张时君 1，杨文琪 1，李凤华 1. 前列腺前角穿刺活检在前列腺癌诊断中的价值[J]. 上海交通大学学报（医学版）, 2019, 39(5): 518-.
[4]	方晓 1, 2，郭建功 1，黄金明 1，樊连城 2. 预后营养指数预测转移性去势抵抗前列腺癌患者阿比特龙初始耐药和预后[J]. 上海交通大学学报（医学版）, 2019, 39(3): 316-.
[5]	陈鸣，傅晓红，吴墅，万永林. 前列腺特异抗原灰区患者前列腺癌的风险预估[J]. 上海交通大学学报（医学版）, 2019, 39(2): 217-.
[6]	刘利杰 1，洪西 1，黄先玉 3，罗静 3，俞建军 1, 2. 前列腺癌中巴豆酰化修饰的测定及与肿瘤分期和分级的相关性[J]. 上海交通大学学报（医学版）, 2018, 38(7): 788-.
[7]	潘玉龙1，齐隽2，周亮1，张彤彤1，李强1. 核糖体蛋白16高表达于前列腺癌并促进肿瘤进展[J]. 上海交通大学学报（医学版）, 2018, 38(4): 394-.
[8]	潘家骅，迟辰斐，董柏君，朱寅杰，邵晓光，王艳青，徐凡，沙建军，黄翼然，薛蔚. 多西他赛联合全雄阻断新辅助疗法治疗高危局部进展性前列腺癌的安全性[J]. 上海交通大学学报（医学版）, 2017, 37(6): 797-.
[9]	樊连城，董柏君，迟辰斐，潘家骅，王艳青，邵晓光，徐凡，上官勋，周立新 #，薛蔚 # . 阿比特龙联合泼尼松治疗转移性去势抵抗性前列腺癌的疗效及预后因素分析#br#[J]. 上海交通大学学报（医学版）, 2017, 37(11): 1483-.
[10]	付什，周娟，王忠 . 脂联素及其受体在前列腺癌中的作用和研究进展[J]. 上海交通大学学报（医学版）, 2017, 37(10): 1434-.
[11]	樊连城，董柏君，迟辰斐，潘家骅，沙建军，黄翼然，周立新，薛蔚. 阿比特龙联合泼尼松治疗未经化疗转移性去势抵抗性前列腺癌的有效性和安全性[J]. 上海交通大学学报（医学版）, 2016, 36(9): 1306-.
[12]	谢华英，陈海燕，张凤，殷焱，路青，曹子昂，白永瑞，吴华伟. 功能磁共振成像与CT在食管癌T分期中的应用价值比较[J]. 上海交通大学学报（医学版）, 2016, 36(7): 1029-.
[13]	陈小溪，吴连明，张晓斐，等. 前列腺癌IVIM弥散加权成像与Gleason评分的相关性研究[J]. 上海交通大学学报（医学版）, 2014, 34(6): 868-.
[14]	杨艳, 陈莉. 前列腺癌患者去势治疗后心理障碍的原因分析及干预策略[J]. , 2011, 31(6): 730-.
[15]	丁奕星, 齐隽. TMPRSS2-ETS融合基因在前列腺癌中的研究进展及临床应用前景[J]. , 2011, 31(6): 852-.

前列腺癌患者血液中PSA、TAP、MACC1的表达及其诊断价值

Diagnostic value of PSA, TAP and MACC1 expression in blood of patients with prostate cancer

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

图/表 3

参考文献 17

相关文章 15

编辑推荐

Metrics